Retatrutide Dosing Guide: How to Use the Most Powerful Fat Loss Peptide
Titration schedule, injection timing, cycle length, and stacking options for retatrutide research
Source: https://indexalabs.com/blog/retatrutide-dosing-guide-protocol Abstract: A practical dosing guide for retatrutide based on published clinical trial protocols. Covers titration schedules, reconstitution, injection technique, cycle length, and evidence-based stacking approaches for metabolic research.
1. Dosing Overview
Retatrutide is a once-weekly subcutaneous injectable peptide. Clinical trials have evaluated doses ranging from 0.5mg to 12mg per week, with dose-dependent weight loss observed across the range.
The key principle in retatrutide dosing is gradual titration — starting at a low dose and increasing over weeks to minimize gastrointestinal side effects while achieving optimal efficacy.
Available Vial Sizes at Indexa Labs:
- 15mg vial
- 20mg vial
- 60mg vial
2. Titration Schedule (Clinical Protocol)
2.1 Phase 2 Trial Titration (12mg Target) The Phase 2 trial used the following escalation schedule:
| Period | Weekly Dose | Duration |
|---|---|---|
| Initiation | 2mg | Weeks 1–4 |
| Step-up 1 | 4mg | Weeks 5–8 |
| Step-up 2 | 8mg | Weeks 9–12 |
| Maintenance | 12mg | Weeks 13+ |
2.2 Conservative Approach Some protocols extend each step to 6 weeks for better GI tolerance:
- Weeks 1–6: 2mg
- Weeks 7–12: 4mg
- Weeks 13–18: 8mg
- Weeks 19+: 12mg
2.3 Signs to Hold or Reduce Dose
- Persistent nausea beyond 7 days at current dose
- Significant GI distress
- Unintended rapid weight loss (>2% per week)
3. Reconstitution & Preparation
3.1 Materials Needed
- Retatrutide lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (1mL, 29–31 gauge)
- Alcohol swabs
3.2 Reconstitution Steps
- Clean vial stoppers with alcohol swabs
- Slowly inject BAC water into the peptide vial (aim at the glass wall, not directly at powder)
- Gently swirl — never shake
- Allow to fully dissolve (1–5 minutes)
- Solution should be clear and colorless
3.3 Concentration Examples
| Vial Size | BAC Water Added | Concentration |
|---|---|---|
| 15mg | 1.5mL | 10mg/mL |
| 20mg | 2mL | 10mg/mL |
| 60mg | 3mL | 20mg/mL |
3.4 Storage After Reconstitution
- Refrigerate at 2–8°C immediately
- Use within 28 days
- Do not freeze reconstituted solution
4. Injection Technique & Timing
4.1 Injection Sites Subcutaneous injection sites include:
- Abdomen (2 inches from navel)
- Upper thigh (front or outer)
- Upper arm (outer area)
Rotate injection sites weekly to prevent lipodystrophy.
4.2 Best Time to Inject Retatrutide can be administered at any time of day, with or without food. Most protocols suggest:
- Morning injection: May help with daytime appetite suppression
- Evening injection: May reduce awareness of initial nausea
- Consistency: Choose one day per week and maintain it
4.3 Missed Dose Protocol If a dose is missed:
- Within 3 days: Administer as soon as possible, then resume normal schedule
- More than 3 days late: Skip and resume on next scheduled day
5. Cycle Length & Duration
5.1 Clinical Trial Duration Phase 2 trials ran for 48 weeks. Phase 3 trials extend to 72+ weeks.
5.2 Research Cycle Recommendations
- Minimum effective cycle: 16 weeks (to complete titration and observe response)
- Standard research cycle: 24–36 weeks
- Extended protocols: 48+ weeks with periodic assessment
5.3 Post-Cycle Considerations Abrupt discontinuation may lead to weight regain. Protocols often include:
- Gradual dose reduction over 4–6 weeks
- Transition to maintenance dose
- Lifestyle and dietary adjustments during taper
6. Stacking Options
6.1 Retatrutide + BPC-157 Some research protocols combine retatrutide with BPC-157 for GI mucosal protection, given the GI side effects associated with GLP-1 agonists.
6.2 Retatrutide + Tesamorelin Combining with the GHRH analog tesamorelin for enhanced visceral fat reduction and GH-mediated lean mass preservation.
6.3 Retatrutide + 5-Amino-1MQ Pairing with 5-Amino-1MQ (NNMT inhibitor) for dual-pathway fat metabolism research.
6.4 Important Stacking Notes
- No clinical data exists on peptide stacking with retatrutide
- All combinations are experimental and require careful monitoring
- Start the primary compound (retatrutide) alone before adding secondary agents
7. Monitoring & Safety
7.1 Recommended Monitoring Schedule
- Baseline: Body weight, waist circumference, blood glucose, HbA1c, lipid panel, liver enzymes
- Monthly: Weight, blood glucose, GI symptom assessment
- Quarterly: Full metabolic panel, body composition (if available)
7.2 Red Flags Requiring Protocol Pause
- Severe or persistent vomiting
- Signs of pancreatitis (severe abdominal pain radiating to back)
- Significant hypoglycemia (especially if combined with insulin or sulfonylureas)
- Allergic reaction at injection site
7.3 GI Management Tips
- Eat smaller, more frequent meals
- Avoid high-fat meals during titration
- Stay well hydrated
- Ginger or peppermint may help manage mild nausea